Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 1/2017

01.02.2017 | Research Article

Availability and quality of illegitimate somatropin products obtained from the Internet

verfasst von: Róbert György Vida, András Fittler, Ivett Mikulka, Eszter Ábrahám, Viktor Sándor, Ferenc Kilár, Lajos Botz

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background Growth hormones are widely available on the Internet for those who want to enhance their physical performance and improve body satisfaction. Illegitimate websites market somatropin injections without medical prescription and encourage misuse. Customers potentially put their health at risk when purchasing parenteral medications online. Objective The objective of our study was to evaluate the online market of no-prescription somatropin products and to analyse and document Internet pharmacy characteristics, distribution and pharmaceutical quality. Setting Websites indexed in Google promoting somatropin for sale direct to patients. Method Websites promoting the sale of growth hormone products were identified and analysed from June to August 2014. Internet vendor sites were evaluated to identify possible patient and medication safety concerns. Website characteristics, delivery time, storage conditions, packaging and attached product information were assessed. Investigation of the somatropin content was achieved using capillary electrophoresis with UV detection and electrospray ionization mass spectrometry. Main outcome measure Accessibility and quality of somatropin injections. Results Seventeen individual Internet vendor websites distributed somatropin products directly to patients, majority (94%) did not require a valid medical prescription before dispensing the products. Majority (70%) of Internet pharmacies displayed no medical information and none (0%) of the vendors displayed any regulatory body logo. All online samples had significantly (p < 0.001) lower somatropin concentration than labelled. Conclusion Our results clearly illustrate that prescription only biologic drugs are widely available online and can be easily accessed by anyone. Unprofessional distribution and handling is likely to cause degradation and possible patient safety concerns.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat McVeigh J, Evans-Brown M, Bellis MA. Human enhancement drugs and the pursuit of perfection. Adicciones. 2012;24(3):185–90.CrossRefPubMed McVeigh J, Evans-Brown M, Bellis MA. Human enhancement drugs and the pursuit of perfection. Adicciones. 2012;24(3):185–90.CrossRefPubMed
2.
Zurück zum Zitat Fittler A, Bősze G, Botz L. Evaluating aspects of online medication safety in long-term follow-up of 136 Internet pharmacies: illegal rogue online pharmacies flourish and are long-lived. J Med Internet Res. 2013;15(9):e199.CrossRefPubMedPubMedCentral Fittler A, Bősze G, Botz L. Evaluating aspects of online medication safety in long-term follow-up of 136 Internet pharmacies: illegal rogue online pharmacies flourish and are long-lived. J Med Internet Res. 2013;15(9):e199.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Graham MR, Ryan P, Baker JS, Davies B, Thomas NE, Cooper SM, et al. Counterfeiting in performance- and image-enhancing drugs. Drug Test Anal. 2009;1(3):135–42.CrossRefPubMed Graham MR, Ryan P, Baker JS, Davies B, Thomas NE, Cooper SM, et al. Counterfeiting in performance- and image-enhancing drugs. Drug Test Anal. 2009;1(3):135–42.CrossRefPubMed
4.
Zurück zum Zitat Jiang H, Wu SL, Karger BL, Hancock WS. Mass spectrometric analysis of innovator, counterfeit, and follow-on recombinant human growth hormone. Biotechnol Prog. 2009;25(1):207–18.CrossRefPubMed Jiang H, Wu SL, Karger BL, Hancock WS. Mass spectrometric analysis of innovator, counterfeit, and follow-on recombinant human growth hormone. Biotechnol Prog. 2009;25(1):207–18.CrossRefPubMed
6.
Zurück zum Zitat United States Pharmacopeia. Somatropin for injection. In United States Pharmacopeia 37, National Formulary 32. Rockville: United States Pharmacopeial Convention Inc.; 2014. p. 4730–2. United States Pharmacopeia. Somatropin for injection. In United States Pharmacopeia 37, National Formulary 32. Rockville: United States Pharmacopeial Convention Inc.; 2014. p. 4730–2.
7.
Zurück zum Zitat European Pharmacopoeia, 7.0-1 ed. Somatropin for injection. Supplement 535th ed.; 2005. p. 3619–21. European Directorate for Quality of Medicines and Health Care. Strasbourg, France; 2014. European Pharmacopoeia, 7.0-1 ed. Somatropin for injection. Supplement 535th ed.; 2005. p. 3619–21. European Directorate for Quality of Medicines and Health Care. Strasbourg, France; 2014.
8.
Zurück zum Zitat Catai JR, Sastre Toraño J, Jongen PM, de Jong GJ, Somsen GW. Analysis of recombinant human growth hormone by capillary electrophoresis with bilayer-coated capillaries using UV and MS detection. J Chromatogr B Biomed Sci Appl. 2007;852(1–2):160–6. Catai JR, Sastre Toraño J, Jongen PM, de Jong GJ, Somsen GW. Analysis of recombinant human growth hormone by capillary electrophoresis with bilayer-coated capillaries using UV and MS detection. J Chromatogr B Biomed Sci Appl. 2007;852(1–2):160–6.
9.
Zurück zum Zitat Arcelloni C, Fermo I, Banfi G, Pontiroli AE, Paroni R. Capillary electrophoresis for protein analysis: separation of human growth hormone and human insulin molecular forms. Anal Biochem. 1993;212(1):160–7.CrossRefPubMed Arcelloni C, Fermo I, Banfi G, Pontiroli AE, Paroni R. Capillary electrophoresis for protein analysis: separation of human growth hormone and human insulin molecular forms. Anal Biochem. 1993;212(1):160–7.CrossRefPubMed
10.
Zurück zum Zitat Orizio G, Merla A, Schulz PJ, Gelatti U. Quality of online pharmacies and websites selling prescription drugs: a systematic review. J Med Internet Res. 2011;13(3):e74.CrossRefPubMedPubMedCentral Orizio G, Merla A, Schulz PJ, Gelatti U. Quality of online pharmacies and websites selling prescription drugs: a systematic review. J Med Internet Res. 2011;13(3):e74.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Malik NN, Khan Y. Personalized medicine: potential impact on the biopharmaceutical industry. Drug Discovery Today. 2010;15(21–22):881–3.CrossRefPubMed Malik NN, Khan Y. Personalized medicine: potential impact on the biopharmaceutical industry. Drug Discovery Today. 2010;15(21–22):881–3.CrossRefPubMed
14.
Zurück zum Zitat Kinch MS, Haynesworth A, Kinch SL, Hoyer D. An overview of FDA-approved new molecular entities: 1827–2013. Drug Discovery Today. 2014;19(8):1033–9.CrossRefPubMed Kinch MS, Haynesworth A, Kinch SL, Hoyer D. An overview of FDA-approved new molecular entities: 1827–2013. Drug Discovery Today. 2014;19(8):1033–9.CrossRefPubMed
15.
16.
Zurück zum Zitat Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: current status and future challenges. BioDrugs. 2013;27(3):203–11.CrossRefPubMed Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: current status and future challenges. BioDrugs. 2013;27(3):203–11.CrossRefPubMed
17.
Zurück zum Zitat Gohil K. Long-acting therapies will expand growth hormone deficiency market. Pharm Ther. 2015;40(11):772–3. Gohil K. Long-acting therapies will expand growth hormone deficiency market. Pharm Ther. 2015;40(11):772–3.
18.
Zurück zum Zitat Høybye C, Cohen P, Hoffman AR, Ross R, Biller BM. Christiansen JS; Growth Hormone Research Society. Status of long-acting-growth hormone preparations—2015. Growth Hormon IGF Res. 2015;25(5):201–6.CrossRef Høybye C, Cohen P, Hoffman AR, Ross R, Biller BM. Christiansen JS; Growth Hormone Research Society. Status of long-acting-growth hormone preparations—2015. Growth Hormon IGF Res. 2015;25(5):201–6.CrossRef
19.
Zurück zum Zitat Navarro R, Dunn JD, Lee PA, Owens GM, Rapaport R. Translating clinical guidelines into practice: the effective and appropriate use of human growth hormone. Am J Manag Care. 2013;19(15 Suppl):s281–9.PubMed Navarro R, Dunn JD, Lee PA, Owens GM, Rapaport R. Translating clinical guidelines into practice: the effective and appropriate use of human growth hormone. Am J Manag Care. 2013;19(15 Suppl):s281–9.PubMed
20.
Zurück zum Zitat Jung FM. Counterfeit protein drugs: how to discover and how to prevent? Eur J Hosp Pharm Pract. 2007;13(3):61–3. Jung FM. Counterfeit protein drugs: how to discover and how to prevent? Eur J Hosp Pharm Pract. 2007;13(3):61–3.
21.
Zurück zum Zitat Casali PG. Executive Committee of ESMO. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2007;18(12):1923–5.CrossRefPubMed Casali PG. Executive Committee of ESMO. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2007;18(12):1923–5.CrossRefPubMed
26.
Zurück zum Zitat Hardin DS. Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin). Biologics. 2008;2(4):655–61.PubMedPubMedCentral Hardin DS. Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin). Biologics. 2008;2(4):655–61.PubMedPubMedCentral
27.
Zurück zum Zitat Svensson J, Johannson G. Long-term efficacy and safety of somatropin for adult growth hormone deficiency. Treat Endocrinol. 2003;2(2):109–20.CrossRefPubMed Svensson J, Johannson G. Long-term efficacy and safety of somatropin for adult growth hormone deficiency. Treat Endocrinol. 2003;2(2):109–20.CrossRefPubMed
28.
Zurück zum Zitat Holt R, Erotokritou-Mulligan I, Sönksen PH. The history of doping and growth hormone abuse in sport. Growth Hormon IGF Res. 2009;19(4):320–6.CrossRef Holt R, Erotokritou-Mulligan I, Sönksen PH. The history of doping and growth hormone abuse in sport. Growth Hormon IGF Res. 2009;19(4):320–6.CrossRef
29.
Zurück zum Zitat Samaras N, Papadopoulou MA, Samaras D, Ongaro F. Off-label use of hormones as an antiaging strategy: a review. Clin Interv Aging. 2014;23(9):1175–86.CrossRef Samaras N, Papadopoulou MA, Samaras D, Ongaro F. Off-label use of hormones as an antiaging strategy: a review. Clin Interv Aging. 2014;23(9):1175–86.CrossRef
30.
Zurück zum Zitat Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics. 2009;37(3):476–86, 396. Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics. 2009;37(3):476–86, 396.
31.
32.
Zurück zum Zitat Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104–15.CrossRefPubMed Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104–15.CrossRefPubMed
33.
Zurück zum Zitat Cittadini A, Berggren A, Longobardi S, Ehrnborg C, Napoli R, Rosén T, et al. Supraphysiological doses of GH induce rapid changes in cardiac morphology and function. J Clin Endocrinol Metab. 2002;87(4):1654–9.CrossRefPubMed Cittadini A, Berggren A, Longobardi S, Ehrnborg C, Napoli R, Rosén T, et al. Supraphysiological doses of GH induce rapid changes in cardiac morphology and function. J Clin Endocrinol Metab. 2002;87(4):1654–9.CrossRefPubMed
34.
Zurück zum Zitat Birzniece V, Nelson AE, Ho KK. Growth hormone and physical performance. Trends Endocrinol Metab. 2011;22(5):171–8.CrossRefPubMed Birzniece V, Nelson AE, Ho KK. Growth hormone and physical performance. Trends Endocrinol Metab. 2011;22(5):171–8.CrossRefPubMed
35.
Zurück zum Zitat Krug O, Thomas A, Walpurgis K, Piper T, Sigmund G, Schänzer W, et al. Identification of black market products and potential doping agents in Germany 2010–2013. Eur J Clin Pharmacol. 2014;70(11):1303–11.CrossRefPubMed Krug O, Thomas A, Walpurgis K, Piper T, Sigmund G, Schänzer W, et al. Identification of black market products and potential doping agents in Germany 2010–2013. Eur J Clin Pharmacol. 2014;70(11):1303–11.CrossRefPubMed
36.
Zurück zum Zitat Kimergård A, McVeigh J, Knutsson S, Breindahl T, Stensballe A. Online marketing of synthetic peptide hormones: poor manufacturing, user safety, and challenges to public health. Drug Test Anal. 2014;6(4):396–8.CrossRefPubMed Kimergård A, McVeigh J, Knutsson S, Breindahl T, Stensballe A. Online marketing of synthetic peptide hormones: poor manufacturing, user safety, and challenges to public health. Drug Test Anal. 2014;6(4):396–8.CrossRefPubMed
37.
Zurück zum Zitat Perls TT, Reisman NR, Olshansky SJ. Provision or distribution of growth hormone for “antiaging”: clinical and legal issues. J Am Med Assoc. 2005;294(16):2086–90.CrossRef Perls TT, Reisman NR, Olshansky SJ. Provision or distribution of growth hormone for “antiaging”: clinical and legal issues. J Am Med Assoc. 2005;294(16):2086–90.CrossRef
38.
Zurück zum Zitat Perls TT. Anti-aging quackery: human growth hormone and tricks of the trade—more dangerous than ever. J Gerontol A Biol Sci Med Sci. 2004;59(7):682–91.CrossRefPubMed Perls TT. Anti-aging quackery: human growth hormone and tricks of the trade—more dangerous than ever. J Gerontol A Biol Sci Med Sci. 2004;59(7):682–91.CrossRefPubMed
Metadaten
Titel
Availability and quality of illegitimate somatropin products obtained from the Internet
verfasst von
Róbert György Vida
András Fittler
Ivett Mikulka
Eszter Ábrahám
Viktor Sándor
Ferenc Kilár
Lajos Botz
Publikationsdatum
01.02.2017
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 1/2017
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-016-0398-y

Weitere Artikel der Ausgabe 1/2017

International Journal of Clinical Pharmacy 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.